Updates in NHL Management App-Analysen für 12. März

In the management of non-Hodgkin lymphoma (NHL), multiple mechanisms of therapy have been developed. These therapies include anti-CD20 antibodies and chimeric antigen receptor T-cell (CAR-T) therapies. With continued developments in NHL management, bispecific antibodies are a promising strategy for use in the relapsed/refractory setting with promising data showing potential for improving outcomes in patient care.